Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II EOX chemotherapy plus Omegaven in incurable oesophago-gastric carcinoma
2011-003950-24Phase 2Terminated
- Sponsor
- University Hospitals of Leicester NHS Trust
- Start
- Jan 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eicosapentaenoic acid + docosahexaenoic acid, epirubicin, oxaliplatin and capecitabine in gastric cancer (GC), esophageal cancer and Esophagogastric Cancer, sponsored by University Hospitals of Leicester NHS Trust. Primary endpoint: Progression-free survival. Started Jan 2012; status: terminated.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acidepirubicinoxaliplatincapecitabine
03
Conditions
gastric cancer (GC)esophageal cancerEsophagogastric Cancer
Beyond the preview
Go deeper on 2011-003950-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003950-24.